Femarelle

This MedLibrary.org supplementary page on Femarelle is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Related Sponsors

BM Pharmacy Generic pharmaceuticals at unbeatable prices. Insomnia, men's health, hair health, pain control. bmpharmacy.com
Online Pharmacy Carisoprodol, tadalafil, sildenafil, vardenafil and more... xlpharmacy.com
MedBasket.com Discreet. Inexpensive. Fast shipping. Great selection. What more can we say? medbasket.com
Frugalmed 2000 reasons to shop with us first. frugalmed.com
Ads by Tiva

Femarelle (DT56a) is as a novel Selective estrogen receptor modulator (SERM)[1] for the treatment of menopause and bone health. DT56a is derived from Soybeans through a unique procedure, producing a stable and standardized compound with a clear fingerprint.


Contents

Mode of Action

Femarelle exerts agonistic (stimulatory) activity on estrogen receptors in the brain and bone[2][3], leading to alleviation of menopausal symptoms such as hot flushes[4] and elevation of Bone mineral density (BMD)[5], while having an antagonistic (blocking) effect on the breast[6] and uterine [7] [8] tissues, thus not causing any cell proliferation in these tissues. Femarelle was found to regenerate the bone through increased osteoblast activity[9], which makes it a unique agent for postmenopausal bone loss by its bone-forming properties. Although affecting estrogen receptors, Femarelle does not change the hormonal blood profile[10], indicating that the body does not recognize it as estrogen. Furthermore, Femarelle was found to have no effect on blood coagulation[11].

Indication

For the relief of menopausal symptoms and the promotion of bone health.


Dosage

1 capsule, twice daily; can be taken with or without food.


Recent Findings

A recent study found that Femarelle has no effect on clotting in both healthy and thrombophilic womenNachtigall L., article in process.


Trade Names

Femarelle (Greece, Italy, Spain, Israel, USA, India, Latvia, Lithuania, Estonia)
Tofupill (Norway, Sweden, Cyprus, Mexico)
Bonfemi (Finland)

References

  1. ^ Somjen D, Katzburg S, Knoll E, et al (May 2007). "DT56a (Femarelle): a natural selective estrogen receptor modulator (SERM)". J. Steroid Biochem. Mol. Biol. 104 (3-5): 252–8. doi:10.1016/j.jsbmb.2007.03.004. PMID 17428655. 
  2. ^ Somjen D, Yoles I (October 2003). "DT56a stimulates creatine kinase specific activity in vascular tissues of rats". J. Endocrinol. Invest. 26 (10): 966–71. PMID 14759068. 
  3. ^ Somjen D, Yoles I (July 2003). "DT56a (Tofupill/Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus". J. Steroid Biochem. Mol. Biol. 86 (1): 93–8. PMID 12943748. 
  4. ^ Yoles I, Yogev Y, Frenkel Y, Hirsch M, Nahum R, Kaplan B (2004). "Efficacy and safety of standard versus low-dose Femarelle (DT56a) for the treatment of menopausal symptoms". Clin Exp Obstet Gynecol 31 (2): 123–6. PMID 15266766. 
  5. ^ Yoles I, Yogev Y, Frenkel Y, Nahum R, Hirsch M, Kaplan B (2003). "Tofupill/Femarelle (DT56a): a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss". Menopause 10 (6): 522–5. doi:10.1097/01.GME.0000064864.58809.77. PMID 14627860. 
  6. ^ Yoles I, Lilling G (January 2007). "Pharmacological doses of the natural phyto-SERM DT56a (Femarelle) have no effect on MCF-7 human breast cancer cell-line". Eur. J. Obstet. Gynecol. Reprod. Biol. 130 (1): 140–1. doi:10.1016/j.ejogrb.2006.02.010. PMID 16580119. 
  7. ^ Somjen D, Yoles I (July 2003). "DT56a (Tofupill/Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus". J. Steroid Biochem. Mol. Biol. 86 (1): 93–8. PMID 12943748. 
  8. ^ Oropeza MV, Orozco S, Ponce H, Campos MG (2005). "Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract". Reprod. Toxicol. 20 (2): 261–6. doi:10.1016/j.reprotox.2005.02.007. PMID 15878261. 
  9. ^ Somjen D, Katzburg S, Lieberherr M, Hendel D, Yoles I (January 2006). "DT56a stimulates gender-specific human cultured bone cells in vitro". J. Steroid Biochem. Mol. Biol. 98 (1): 90–6. doi:10.1016/j.jsbmb.2005.08.002. PMID 16243521. 
  10. ^ Yoles I, Yogev Y, Frenkel Y, Hirsch M, Nahum R, Kaplan B (2004). "Efficacy and safety of standard versus low-dose Femarelle (DT56a) for the treatment of menopausal symptoms". Clin Exp Obstet Gynecol 31 (2): 123–6. PMID 15266766. 
  11. ^ segparis2007.com/docs/Livre_du_congres_-_Congress_book.pdf

External Links

Femarelle Official Website

Wikipedia content modification information:

  • This page was last modified on 9 September 2008, at 16:56.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Femarelle".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.